Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of GDC-0077 plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in PIK3CA-mutant HR-positive HER2-negative advanced breast cancer
CTR20202249Phase 3Active
- Sponsor
- Roche
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of inavolisib in breast cancer, sponsored by Roche. Started Apr 2021; status: active.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20202249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202249.